Despite the growing amount of attention the HIV clinical care world has paid in recent years to the inextricable ties between mental health and physical health outcomes, we’ve still got a long ways to go when it comes to understanding the cause and effect of mental health issues in HIV.
Founded in 2002, TheBodyPro exists to inform and support the HIV workforce -- the vast constellation of people working on the front lines of HIV education, prevention, care, and services. Whether you're a physician or a case manager; a registered nurse or a licensed social worker; a medical technician or a therapist; they're here to provide you with up-to-date information, valuable perspectives, and authentic professional voices.
Today we’ll examine new data on:
Higher rates of insomnia among people living with HIV (PLWH)—but with very low treatment rates.
Trends in multimorbidity diagnosis among aging PLWH.
The (super-low) frequency of viral load control loss in the modern HIV treatment era.
The relative appeal of different methods of HIV self-test dissemination throughout the world.
NIH Experts Call for Accelerated Research to Address Concurrent HIV and COVID-19 Pandemics
The COVID-19 pandemic is affecting people with or at risk for HIV both indirectly, by interfering with HIV treatment and prevention services, and directly, by threatening individual health. An effective response to these dual pandemics requires unprecedented collaboration to accelerate basic and clinical research, as well as implementation science to expeditiously introduce evidence-based strategies into real-world settings. This message comes from a review article co-authored by Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and colleagues published in the Journal of Infectious Diseases.
Check out this week's literature:
Clinical trial data show that daily oral tenofovir disoproxil fumarate (TDF)–based pre-exposure prophylaxis (PrEP) safely protects against HIV infection across diverse exposures, sexes, and gender identities. However, maintaining adherence is one of the greatest challenges to effective PrEP implementation—a challenge that may be overcome through use of long-acting (LA) PrEP. Here, I share my thoughts on important new data on 2 promising LA PrEP agents, islatravir and cabotegravir, presented at the 4th HIV Research for Prevention Conference (HIVR4P // Virtual).
Hosted by the Allegany County NAACP 7007
All events from Saturday - Sunday are Free for the community.